{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.72","upperLimit":"26.81","value":"19.45"},{"groupId":"OG001","lowerLimit":"13.67","upperLimit":"25.00","value":"18.60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"description":"Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daratumumab 8 milligram per kilogram (mg/kg) every 4 weeks (Q4W) until disease progression or unacceptable toxicity.","id":"OG000","title":"Daratumumab 8 mg/kg"},{"description":"Daratumumab 16 mg/kg weekly for 8 weeks; then every 2 weeks (Q2W) for 16 weeks; then Q4W until disease progression or unacceptable toxicity.","id":"OG001","title":"Daratumumab 16 mg/kg"}],"paramType":"MEDIAN","populationDescription":"All treated analysis set included all participants who received at least 1 dose of daratumumab.","reportingStatus":"POSTED","timeFrame":"Approximately up to 3 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}